News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PLC Systems, Inc.' RenalGuard® Demonstrated at Major Latin American Cardiology Meeting


8/13/2012 11:39:39 AM

MILFORD, Mass., Aug. 13, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that its innovative product, RenalGuard®, was demonstrated at SOLACI 2012, the annual meeting of the Latin American Society of Interventional Cardiology, August 8-10, 2012, in Mexico City, Mexico. Girlow USA, PLC's distributor in Latin America for all countries with the exception of Brazil, exhibited RenalGuard in its booth at the event, demonstrating its ease of use along with scientific data supporting its efficacy to potential customers in this important geographic area. More than 2,000 clinicians and medical professionals attended this event.

"We were pleased by the level of interest in RenalGuard from cardiologists from across Latin America who attended SOLACI. They recognize the need to find a therapy like RenalGuard to protect their patients who may be at risk of developing Contrast Induced Nephropathy (CIN)," commented Andrew Halpert, PLC's Director of Marketing. "We are working closely with our experienced distribution partner, Girlow, to spur adoption of RenalGuard in this important market."

About PLC Systems

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC.

Contact: Mary T. Conway
508-520-2545
mconway@plcmed.com

SOURCE PLC Systems Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES